Chinese medical portal censored after doubting herbal 'COVID remedy'

DXY's article was part of a wave of reports that caused shares in Lianhua Qingwen's producer -- one of China's largest tradition
DXY's article was part of a wave of reports that caused shares in Lianhua Qingwen's producer -- one of China's largest traditional medicine companies -- to plunge.

A popular Chinese medical information site has been censored by authorities for "violation of relevant laws and regulations", months after its criticism of a government-backed herbal COVID-19 treatment sent shares in a pharmaceutical giant tumbling.

DXY, which counts tech giant Tencent among its investors and runs a host of health-related services, previously questioned the value of Lianhua Qingwen, a herbal remedy marketed for fever and , as a COVID-19 treatment.

China approved the concoction—made up of ingredients like honeysuckle and apricot seeds—as a COVID-19 treatment in 2020, and it was distributed to Shanghai residents during the city's outbreak this year.

DXY's article, which has now been deleted from its website, was part of a wave of reports that caused shares in Lianhua Qingwen's producer—one of China's largest traditional medicine companies—to plunge.

The website has now been banned from posting on at least five of its Weibo , with a notice at the top of its official page saying that due to "violation of relevant laws and regulations, this user is currently prohibited from posting".

DXY's official WeChat accounts, which typically publish multiple articles a day on medical topics, have not been updated since Monday.

The Weibo notice did not specify which regulations had been violated by DXY, which did not immediately respond to AFP's request for comment.

'No right to ban them'

The Chinese government has increasingly promoted at home and abroad in recent years, often with nationalistic undertones.

DXY's coverage prompted criticism that it was targeting traditional Chinese medicine (TCM) in order to promote Western pharmaceuticals.

The decision to freeze DXY's social media accounts was lauded by some Weibo users, who accused the company of working with "anti-China forces" and peddling .

"For this vicious thing eating the anti-Chinese capitalists' dog food, the best days are in the past," one Weibo user wrote.

But others lamented the loss of a valued source of misinformation-free medical guidance and said they disagreed with the censorship.

"My mother used to be the kind of person who would make her kids eat chicken gallbladder for fevers," one wrote, crediting DXY with giving her parent access to modern medical information.

"You have the right to (criticise) DXY on Weibo, but you don't have the right to ban them," the user wrote.

The United States and other countries have warned there is no evidence Lianhua Qingwen works to prevent or cure COVID-19, even as it has increasingly been promoted by government authorities in China and Hong Kong.

The US Food and Drug Administration has said it has not approved Lianhua Qingwen and that coronavirus-related claims about it were "not supported by competent and reliable scientific evidence".

Beijing issued its first white paper on TCM in 2016, laying out plans to build medicine centres and dispatch practitioners to developing countries in Africa and Southeast Asia.

President Xi Jinping has described TCM as a "treasure of Chinese civilisation" and has said that it should be given as much weight as other treatments.

Beijing's National Health Commission has also dispatched TCM practitioners as part of its medical reinforcement teams sent to fight COVID-19 outbreaks across the country.

© 2022 AFP

Citation: Chinese medical portal censored after doubting herbal 'COVID remedy' (2022, August 11) retrieved 22 May 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Herbal remedies for the coronavirus spark debate in China


Feedback to editors